Sanja Dacic, MD, PhD
Professor of PathologyCards
About
Research
Publications
2025
Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.
Chaft J, Weder W, He J, Chen K, Hochmair M, Shih J, Lee S, Lee K, Nhung N, Saeteng S, Andrade Teixeira C, Escriu C, Martinez-Marti A, Blakely C, Yatabe Y, Dacic S, Huang X, Rukazenkov Y, Dayal A, Tsuboi M. Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA. Journal Of Clinical Oncology 2025, 43: 8001-8001. DOI: 10.1200/jco.2025.43.16_suppl.8001.Peer-Reviewed Original ResearchRandomized Phase II Clinical Trial of Sulforaphane in Former Smokers at High Risk for Lung Cancer.
Yuan J, Kensler T, Dacic S, Hartman D, Wang R, Balogh P, Sufka P, Turner M, Fuhrer K, Seigh L, Pham Y, Adams-Haduch J, Valacchi G, Singh S, Herman J, Wilson D. Randomized Phase II Clinical Trial of Sulforaphane in Former Smokers at High Risk for Lung Cancer. Cancer Prevention Research 2025, 18: 335-345. PMID: 40041932, DOI: 10.1158/1940-6207.capr-24-0386.Peer-Reviewed Original ResearchComparative performance of PD‐L1 scoring by pathologists and AI algorithms
Plass M, Olteanu G, Dacic S, Kern I, Zacharias M, Popper H, Fukuoka J, Ishijima S, Kargl M, Murauer C, Kalson L, Brcic L. Comparative performance of PD‐L1 scoring by pathologists and AI algorithms. Histopathology 2025, 87: 90-100. PMID: 39961605, PMCID: PMC12129605, DOI: 10.1111/his.15432.Peer-Reviewed Original Research
2024
Sex-based differences in CEACAM5 expression in lung cancer
Woodard G, Kane E, Todorovic N, Prince S, Dacic S, Chen L. Sex-based differences in CEACAM5 expression in lung cancer. Translational Cancer Research 2024, 13: 6394-6402. PMID: 39697744, PMCID: PMC11651760, DOI: 10.21037/tcr-24-983.Peer-Reviewed Original ResearchMA08.12 Semi-Sold Lung Nodule Growth Rates, Need for Treatment, and Cancer-Specific Verses All-Cause Mortality in a Large North American Population
Woodard G, Kane E, Prince S, Blasberg J, Dhanasopon A, Boffa D, Mase V, Dacic S, Bader A, Detterbeck F. MA08.12 Semi-Sold Lung Nodule Growth Rates, Need for Treatment, and Cancer-Specific Verses All-Cause Mortality in a Large North American Population. Journal Of Thoracic Oncology 2024, 19: s87. DOI: 10.1016/j.jtho.2024.09.156.Peer-Reviewed Original ResearchEP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer
Ermer T, Kim S, Goldberg S, Zolfaghari E, Blasberg J, Boffa D, Herbst R, Politi K, Schalper K, Dacic S, Woodard G. EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s543-s544. DOI: 10.1016/j.jtho.2024.09.1007.Peer-Reviewed Original ResearchChallenges in Thoracic Pathology
Dacic S, Brcic L. Challenges in Thoracic Pathology. Advances In Anatomic Pathology 2024, 31: 281-282. PMID: 38975708, DOI: 10.1097/pap.0000000000000456.Peer-Reviewed Original ResearchNeoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
Spicer J, Cascone T, Wynes M, Ahn M, Dacic S, Felip E, Forde P, Higgins K, Kris M, Mitsudomi T, Provencio M, Senan S, Solomon B, Tsao M, Tsuboi M, Wakelee H, Wu Y, Chih-Hsin Yang J, Zhou C, Harpole D, Kelly K. Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer. Journal Of Thoracic Oncology 2024, 19: 1373-1414. PMID: 38901648, DOI: 10.1016/j.jtho.2024.06.010.Peer-Reviewed Original ResearchThe Proposed Ninth Edition TNM Classification of Lung Cancer
Detterbeck F, Woodard G, Bader A, Dacic S, Grant M, Park H, Tanoue L. The Proposed Ninth Edition TNM Classification of Lung Cancer. Chest 2024, 166: 882-895. PMID: 38885896, DOI: 10.1016/j.chest.2024.05.026.Peer-Reviewed Original ResearchShould the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors?
Woodard G, Dacic S. Should the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors? Journal Of Thoracic Oncology 2024, 19: 663-665. PMID: 38719420, DOI: 10.1016/j.jtho.2024.01.004.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
News
- September 08, 2025Source: OncoDaily
Dr. Sanja Dacic Awarded the 2025 Mary J. Matthews Pathology/Translational Research Award
- July 07, 2025
International Exchange Fosters Clinical and Research Collaboration
- June 12, 2025
Pathology, Laboratory Medicine Residents, Fellows Feted at Graduation Ceremony
- April 11, 2025Source: Yale Medicine
Understanding Cancer Language: Tumor Terms Patients Should Know
Get In Touch
Contacts
Email